us-life-sciences-research-and-development-b

Perspectives

Life sciences research and development insights

Reshaping R&D innovation. Data-driven. Digitally enabled. Patient-focused.

Innovation remains imperative amid increasing pricing pressures, growing market share for generic pharmaceuticals and biosimilars and looming patent cliffs. However, new avenues -- enabled by real-world evidence, translational medicine, big data analytics, digital health and other advanced technologies and innovations – offer life sciences companies new opportunities to improve R&D efficiencies and returns and elevate the patient experience.

See you at DIA!

ConvergeHEALTH by Deloitte is excited to sponsor DIA’s 2023 Global Annual Meeting. The event is taking place from June 25-29th at the Boston Convention and Exhibition Center in Boston, MA. Are you planning on attending? Check out our sessions:

Evolving the Promise of AI in Pharmacovigilance to Reality

  • Date/time: Monday, June 26 from 12:45 - 1:15 PM
  • Location: Innovation theater #1

Impact of Generative AI across the Value Chain

  • Date/time: Tuesday, June 27 from 11:50 AM - 12:20 PM
  • Location: Innovation theater #2

Also, be sure to visit booth #900 for a round of mini golf. While you’re there, learn more about our life sciences product portfolio including:

  • ElevateSafety: Watch a demo of our cutting-edge pharmacovigilance platform that empowers you to elevate your safety intelligence approach with confidence.
  • SFL Scientific: Explore how AI investment can provide unique opportunities for life sciences leaders to transform their business.

Transforming R&D with emerging technologies

Life Sciences R&D organizations are under increasing pressure to produce a sustainable return on capital given shifts in the market, regulatory and reimbursement environment. While the industry has recently produced groundbreaking innovation that has the potential to truly transform global health, scaling the impact will require rethinking and transforming the traditional R&D model. Advanced technologies and innovations such as robotics, artificial intelligence (AI), and cognitive automation, real-world evidence (RWE), digital health and telemedicine, can impact R&D across the entire value chain – from drug discovery to clinical trials and regulatory reporting. They will also impact the talent models of many organizations, and how R&D is conducted in the future.

Wearables, connected devices, mHealth and telemedicine all have potential to transform clinical trial design, recruitment and retention, as well as exponentially expand the data points collected. These same technologies offer new opportunities for manufacturers to harness deeper insights into pharmacovigilance and patient safety. With new regulatory pathways for real-world data, advanced information management and analytics, technologies can enable R&D organizations to access, analyze, and meaningfully act on RWE to advance drug discovery. Similarly, robotic and cognitive automation can enable cost efficiency, productivity gains, and quality/compliance improvements in clinical trials and regulatory information management.

How we can help

Strategically applying digital innovation can help lead to a vibrant and sustainable life sciences R&D industry focused on high-value outcomes – an objective that is vital to the future of biopharma companies and to the future of global public health.

-Neil Lesser, Life Sciences R&D Leader, Deloitte Consulting LLP

Watch the playlist

Get in touch

Principal, Deloitte Consulting LLP

anbolt@deloitte.com

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Insert Custom CSS fragment. Do not delete! This box/component contains code needed on this page. This message will not be visible when page is activated.
+++ DO NOT USE THIS FRAGMENT WITHOUT EXPLICIT APPROVAL FROM THE CREATIVE STUDIO DEVELOPMENT TEAM +++

Did you find this useful?